Mimicking a cure
14 August, 2013 by Fiona WylieA collaboration of Melbourne scientists who describe themselves as a “happy confluence” is shedding much-needed light on how the body controls nervous system myelination, and how their tiny peptide ‘mimic’ could help patients with neurodegenerative disease.
DNA - a silent witness
07 August, 2013 by Graeme O’NeillForensic science is about to be transformed with the use of new technology to predict a person’s physical appearance - a molecular photofit derived from DNA found at a crime scene.
Supercomputer switched on
01 August, 2013Ranked as one of the largest supercomputers in the world, Australia’s fastest supercomputer has been turned on.
Big genome
17 July, 2013 by Graeme O'NeillDebate continues about the claim that proteins interact with 80% of the human genome and whether this much regulation is required for a functional human being.
GTG posts record BREVAGen sales growth
02 July, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) said its BREVAGen genetic testing business has been growing faster every quarter since its expansion to the US in mid-2011.
Genetic variations found in people with allergies
01 July, 2013Genetic differences between people who develop allergies and those who don’t have been identified.
US patent verdict “troubling”: BIO
19 June, 2013 by Dylan Bushell-EmblingThe head of US biotech industry group BIO has argued that the recent Supreme Court verdict on DNA patents could cause problems but he welcomed the ruling that the restrictions do not apply to composite DNA (cDNA) that is distinguishable from naturally occurring sequences.
GTG expects no impact from US gene verdict
18 June, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) believes a US Supreme Court patent ruling should have no material impact on its commercial operations.
Bioengineering a new kidney
18 June, 2013Queensland researchers have reprogrammed adult kidney cells to act as stem cells to repair damaged kidneys.
Timing it right
05 June, 2013 by Susan WilliamsonJohn Shine reflects on his impressive career as a research scientist, including a foray or two into the world of biotech and 22 years as head of the Garvan Institute - he says it helped being in the right place at the right time.
Resistance to computation is futile
22 May, 2013 by Andrew Lonie*Associate Professor Andrew Lonie outlines the importance of bioinformatics to today’s research labs and showcases one researcher who talks about how it has changed the way she works.
10 commandments for next-gen sequencing
15 May, 2013 by Dan KoboldtGeneticist Dan Koboldt from the Genome Institute at Washington University in St Louis gives his decalogue on next-generation sequencing.
GTG settles licensing dispute in US
06 May, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has resolved a dispute surrounding a licence to its non-coding DNA patents first awarded in 2004.
GTG settles another DNA patent suit
30 April, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has announced a second settlement agreement in as many days for patent infringement lawsuits it filed in the US.
GTG wins new DNA patent settlement
29 April, 2013 by Dylan Bushell-EmblingGTG’s (ASX:GTG) US enforcement efforts for its non-coding DNA patents have yielded a settlement with another genetic testing company.
